Stemrim Inc. (4599)
JPX JPX Primary Summary
Stemrim Inc. (4599) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Stemrim Inc. ever had a stock split?
Stemrim Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Masatsune Okajima CEO | JPX Exchange | JP3399690001 ISIN |
| Japan Country | 45 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
StemRIM is a pioneering biotechnology company established in 2006, stationed in Ibaraki, Japan. The company's focus lies in the realm of regenerative medicine, particularly aiming at the development of innovative treatments for various intractable diseases. Leveraging advanced scientific research and clinical trials, StemRIM is on the forefront of creating regeneration induction medicines that hold the potential to significantly improve patient outcomes for diseases that currently have limited treatment options.
Products and Services
PJ1
PJ1 represents StemRIM’s flagship product currently in Phase II clinical trials. It encompasses HMGB1 peptides utilized as regeneration induction medicine. Targeted diseases for PJ1 treatment include epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Its main goal is to pioneer advancements in the treatment of these conditions, offering new hope through regenerative medicine techniques.
PJ2 and PJ3
These are in the pre-clinical stage, devised to combat multiple tissue damage diseases. The development of PJ2 and PJ3 underscores StemRIM's commitment to expanding its portfolio of regenerative medicines. Each aims to usher in a novel approach for repairing and regenerating damaged tissues in multiple disease conditions, potentially revolutionizing the way these ailments are treated.
PJ4
PJ4 introduces an innovative autologous cell sampling device, currently under development for medical treatment applications. This device is designed to streamline the process of collecting autologous cells, which are cells derived from one's own body, for use in various regenerative medicine therapies. The ease and efficiency of cell collection facilitated by PJ4 could significantly enhance therapeutic outcomes and patient experience.
PJ5
StemRIM’s PJ5 delves into the advanced territory of stem cell gene therapy, still in the pre-clinical stage. This product focuses on the use of gene modification within stem cells to treat diseases, offering a cutting-edge approach to regenerative medicine. By harnessing the power of stem cells combined with genetic engineering, PJ5 aims to provide groundbreaking treatment options for disorders that currently lack effective therapies.
